| Developers: | Genentech |
| Date of the premiere of the system: | February 2022 |
| Branches: | Pharmaceuticals, medicine, healthcare |
2022: Release of the drug
On January 28, 2022, Genentech, part of the Roche group of companies, introduced a drug for the treatment of wet, or neo-vascular, age-related macular degeneration and diabetic macular edema. Both diseases are the two leading causes of adult vision loss in the US. Vabysmo will be available in the United States until the end of February 2022.
The drug Vabysmo is aimed at two pathways for the development of disease associated with a number of vision-threatening retinal conditions, and inhibits them by neutralizing angiopoietin and vascular endothelial growth factor. Vabysmo improves and maintains vision at intervals of one to four months during the first year after four initial monthly doses, based on an assessment of patient anatomy and vision results. Standard treatment for the wet form of age-related macular degeneration (AMD) and diabetic macular edema (DMO) usually requires injections into the eyes every one to two months.
 | Vabysmo represents an important step forward for ophthalmology. This is the first important step forward in treating retinal diseases such as wet macular degeneration and diabetic macular edema. With the drug, we have the opportunity to offer patients a medicine that can improve their vision, potentially reducing the burden on treatment by reducing the number of injections over time, said Charles Wykoff, research director at Retina Consultants of Texas in Houston and a phase III researcher at Vabysmo. |  |
Studies have shown that patients treated with the medical drug at intervals of up to four months achieved no worse visual improvement compared to the aflibercept used every two months during the first year. Vabysmo was generally well tolerated in all four trials with a favorable benefit-risk profile. The most common adverse reaction of ≥5% in patients treated with Vabysmo was conjunctival hemorrhage 7%. Two scientific articles on these annual results were published in The Lancet magazine in January 2022.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |